Phase 1 Study Of Elotuzumab And Peripheral Blood Mononuclear Cell Reconstitution In Combination With Autologous Stem Cell Transplantation And Lenalidomide Maintenance For Multiple Myeloma

Introduction: Elotuzumab is a humanized IgG kappa monoclonal antibody against SLAMF7 that is approved in combination with lenalidomide and dexamethasone for relapsed myeloma. This agent promotes antibody-dependent, cell-mediated cytotoxicity (ADCC) and activation of natural killer (NK) cells to kill tumor cells through ligation of the target. We hypothesized that the addition of elotuzumab and autologous peripheral blood mononuclear cell (PBMC) infusion (to provide NK cells post-transplant) to standard-of-care autologous hematopoietic stem cell transplantation (ASCT) and lenalidomide maintenance for consolidation therapy in myeloma patients will be safe and feasible. This strategy may target residual disease and promote adaptive anti-myeloma immunity, resulting in long-term maintenance of a minimal disease state.